Gossamer Bio (GOSS) Competitors $3.11 +0.34 (+12.27%) Closing price 04:00 PM EasternExtended Trading$3.12 +0.02 (+0.48%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GOSS vs. DNLI, IBRX, AGIO, IDYA, OCUL, HRMY, IRON, CGON, RXRX, and ANIPShould you be buying Gossamer Bio stock or one of its competitors? The main competitors of Gossamer Bio include Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Harmony Biosciences (HRMY), Disc Medicine (IRON), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical products" industry. Gossamer Bio vs. Its Competitors Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Disc Medicine CG Oncology Recursion Pharmaceuticals ANI Pharmaceuticals Gossamer Bio (NASDAQ:GOSS) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation. Is GOSS or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Denali Therapeutics' return on equity of -40.79% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer Bio-344.81% -1,774.72% -46.73% Denali Therapeutics N/A -40.79%-36.39% Do institutionals & insiders believe in GOSS or DNLI? 81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 6.7% of Gossamer Bio shares are owned by insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, GOSS or DNLI? Gossamer Bio has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Do analysts rate GOSS or DNLI? Gossamer Bio currently has a consensus target price of $8.50, indicating a potential upside of 173.31%. Denali Therapeutics has a consensus target price of $33.50, indicating a potential upside of 128.83%. Given Gossamer Bio's higher possible upside, equities research analysts clearly believe Gossamer Bio is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12 Which has better valuation and earnings, GOSS or DNLI? Gossamer Bio has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M6.17-$56.53M-$0.62-5.02Denali Therapeutics$330.53M6.48-$422.77M-$2.80-5.23 Does the media favor GOSS or DNLI? In the previous week, Gossamer Bio and Gossamer Bio both had 12 articles in the media. Denali Therapeutics' average media sentiment score of 1.40 beat Gossamer Bio's score of 0.98 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDenali Therapeutics beats Gossamer Bio on 11 of the 16 factors compared between the two stocks. Get Gossamer Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GOSS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOSS vs. The Competition Export to ExcelMetricGossamer BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$629.84M$3.18B$5.83B$10.07BDividend YieldN/A2.26%5.25%4.53%P/E Ratio-5.027.4956.6922.18Price / Sales6.17453.06536.77117.75Price / CashN/A45.8737.4259.95Price / Book23.929.6011.536.20Net Income-$56.53M-$53.33M$3.29B$270.65M7 Day Performance20.54%0.61%0.44%2.77%1 Month Performance76.70%11.11%10.84%8.83%1 Year Performance237.86%12.61%61.62%27.49% Gossamer Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOSSGossamer Bio3.8896 of 5 stars$3.11+12.3%$8.50+173.3%+197.8%$629.84M$114.70M-5.02180News CoverageOptions VolumeGap UpHigh Trading VolumeDNLIDenali Therapeutics4.3497 of 5 stars$15.27-2.4%$33.62+120.1%-40.0%$2.23B$330.53M-5.45430News CoveragePositive NewsAnalyst ForecastIBRXImmunityBio2.8257 of 5 stars$2.34+0.4%$10.75+359.4%-27.6%$2.21B$14.74M-4.87590Analyst ForecastAGIOAgios Pharmaceuticals4.2463 of 5 stars$37.71-1.2%$56.33+49.4%-17.7%$2.19B$36.50M3.43390Insider TradeAnalyst RevisionIDYAIDEAYA Biosciences4.0993 of 5 stars$24.55-1.5%$47.10+91.9%-32.1%$2.15B$7M-6.4880Trending NewsAnalyst ForecastOCULOcular Therapeutix3.7865 of 5 stars$12.21-2.5%$17.20+40.9%+52.6%$2.12B$63.72M-9.54230Positive NewsHRMYHarmony Biosciences4.5382 of 5 stars$36.89-2.8%$51.00+38.2%-7.8%$2.12B$772.53M11.90200Positive NewsIRONDisc Medicine2.6973 of 5 stars$59.650.0%$98.30+64.8%+16.6%$2.07BN/A-13.3430News CoveragePositive NewsCGONCG Oncology2.4422 of 5 stars$26.82+0.4%$54.30+102.5%-11.8%$2.04B$551K-15.1561Trending NewsAnalyst ForecastInsider TradeRXRXRecursion Pharmaceuticals2.3434 of 5 stars$4.70-3.3%$7.00+48.9%-23.2%$2.04B$58.84M-2.64400Positive NewsANIPANI Pharmaceuticals3.9323 of 5 stars$93.50+1.0%$84.75-9.4%+68.4%$2.03B$614.38M-121.43600Analyst Forecast Related Companies and Tools Related Companies DNLI Competitors IBRX Competitors AGIO Competitors IDYA Competitors OCUL Competitors HRMY Competitors IRON Competitors CGON Competitors RXRX Competitors ANIP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOSS) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gossamer Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gossamer Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
